MBX 5765 / MBX Biosci - LARVOL DELTA

Nomination of MBX 5765 as amycretin prodrug development candidate (The Manila Times) - "In May 2026, MBX nominated MBX 5765 as its lead amycretin prodrug development candidate. Enabled by the Company's proprietary PEP platform, MBX 5765 combines GLP-1, GIP, GCG, and dual amylin and calcitonin receptor agonist (DACRA) activity in a single peptide construct. The differentiated mechanism of MBX 5765 is designed for once-monthly dosing, superior efficacy and improved tolerability. IND-enabling studies are ongoing."

Pipeline update • Obesity